| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | -699.18% | -791.27% | -794.04% | 51.56% | 38.41% | -388.88% | -2199.72% | -1112.60% | -3009.49% |
| EBITDA Margin | -682.14% | -771.65% | -772.09% | 51.94% | 38.89% | -383.12% | -2159.00% | -1097.43% | -3000.07% |
| Net Margin | -638.87% | -703.40% | -713.76% | 31.92% | 48.25% | -391.09% | -2158.98% | -1086.28% | -2579.47% |
| Current Ratio | 5.54 | 8.71 | 9.05 | 4.93 | 4.58 | 7.80 | 6.81 | 2.95 | — |
| Quick Ratio | 5.54 | 8.71 | 9.05 | 4.93 | 4.58 | 7.80 | 6.81 | 2.95 | — |
| Debt / Equity | — | — | — | — | — | — | — | — | — |
| ROE | -57.23% | -45.37% | -38.68% | 24.82% | 36.92% | -41.66% | -41.20% | 64.68% | — |
| ROA | -43.68% | -37.31% | -32.05% | 18.41% | 27.05% | -32.51% | -34.11% | -60.48% | — |
| Asset Turnover | 0.07 | 0.05 | 0.04 | 0.58 | 0.56 | 0.08 | 0.02 | 0.06 | — |
| Book Value / Share | 5.52 | 8.44 | 11.86 | 15.41 | 10.73 | 6.02 | 13.97 | -23.37 | — |
Vir Biotechnology Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and advances immune-based therapies to treat and prevent serious infectious diseases and cancer. The company leverages its next-generation antibody platform and PRO-XTEN protease-releasable masking technology to power the immune system against unmet medical needs. Its lead program features the combination of tobevibart, a broadly neutralizing monoclonal antibody, and elebsiran, a siRNA targeting hepatitis B virus, in Phase 3 trials through the ECLIPSE registrational program for chronic hepatitis delta virus. In oncology, Vir Biotechnology advances PRO-XTEN dual-masked T-cell engagers, including VIR-5500 targeting PSMA for metastatic castration-resistant prostate cancer, VIR-5818 for HER2-expressing tumors, and VIR-5525 for EGFR-expressing solid tumors, all in Phase 1 development. Preclinical efforts target influenza, RSV, human metapneumovirus, HPV, HIV, and other indications. Founded in 2016 and headquartered in San Francisco, California, Vir Biotechnology focuses on immunology-driven innovation across infectious diseases and oncology to deliver potentially transformative medicines.